Patent Anticipation – 35 U.S.C. § 102; Novelty – 35 U.S.C. § 103; and Patent-eligible subject matter – 35 U.S.C. § 101.

Patent Anticipation - 35 U.S.C. § 102; Novelty - 35 U.S.C. § 103; and Patent-eligible subject matter - 35 U.S.C. § 101. Please join us on Monday, September 29, 2025, at noon, where we will discuss a recent decisions made by the Court of Appeals for the Federal Circuit regarding patent anticipation – section 102, [...]

AIT v Salesforce – war story update

Patent suits can be like the War of the Roses, or Bleak House. Though most patent suits end pretty quickly, high value cases often pend for a long time. Our firm represents a patent owner in one such suit. Bleak House cover In November 2013, our client Applications in Internet Time, LLC sued [...]

Federal Circuit Dismantles “Rigid” Rosen-Durling Test for Design Patent Obviousness in Light of KSR; USPTO Promptly Issues New Guidance

Federal Circuit Dismantles “Rigid” Rosen-Durling Test for Design Patent Obviousness in Light of KSR; USPTO Promptly Issues New Guidance On February 5, 2024, the Federal Circuit sat en banc to hear oral arguments in a closely watched case concerning design patent obviousness standards in a dispute between LKQ (an aftermarket auto-parts provider), and General Motors [...]

Two Recent Federal Circuit Patent Cases

Objective Indicia of Nonobviousness and Restrictive Scope of Patent Reissue Please join us on Monday, September 11, 2023, where we will discuss two recent precedential opinions from the U.S. Court of Appeals for the Federal Circuit in the patent sphere addressing [1] when evidence of objective indicia of nonobviousness is correctly argued and [2] issues [...]

By |2023-11-09T13:30:10-08:00September 8th, 2023|Guest Speaker, Obviousness, Reissue, Patent|0 Comments

CAFC re: Recapture During a Broadening Reissue; and CAFC re: Expert Witnesses and Obviousness

SoCal IP Law Institute MCLE meeting of August 15, 2022 - CAFC re: Recapture During a Broadening Reissue; and CAFC re: Expert Witnesses and Obviousness. Please join us on Monday, August 15, 2022 at Noon , where we will discuss CAFC re: Recapture During a Broadening Reissue; and CAFC re: Expert Witnesses and Obviousness. For [...]

Analogous Prior Art & Moderna-NIH Patent conflict

Please join us on Monday, March 14, 2022 at 12:00 pm, where we will discuss the concept of Analogous Prior Art in Obviousness rejections, as well as delve into the issues in the Moderna-NIH conflict over Covid vaccine patent rights. Please see Analogous Prior Art slides here. Please see Moderna-NIH slides here, and patent filing [...]

Tattoo Copyright Infringement and Post-Brexit Trademark Considerations

Tattoo Copyright Infringement and Post-Brexit Trademark Considerations For our weekly SoCal IP Institute meeting on Monday, June 7, 2021, Chris Kopitzke will lead a discussion of the legal issues arising from unauthorized copying of a photograph for a tattoo and will highlight selected trademark responsibilities resulting from Brexit.   What happens when a celebrity tattoo [...]

The Trademark Modernization Act of 2020

For our weekly SoCal IP Institute meeting on Monday, May 24, 2021, 1:00 pm PT, Michael Harris will lead a discussion of the Trademark Modernization Act. The Trademark Modernization Act of 2020 (TMA) (tm modernization act) is now law, but it needs PTO rules before TMA will become effective. The proposed rules are at TMA [...]

Two Recent Federal Circuit Patent Cases

For our weekly SoCal IP Institute meeting on Monday, May 17, 2021 at 1:00 pm, Mark Goldstein will lead a discussion of two recent Federal Circuit patent cases. Free Stream Media Corp. dba Samba TV v. Alphonso Inc. (Fed. Cir. May 11, 2021, 2019-1506, 2019-213) Samba sued Alphonso in two courts, asserting infringement of its [...]

SoCal IP MCLE meeting May 10, 2021

Our weekly SoCal IP Institute meeting on Monday, May 10, 2021 will be a discussion of two Federal Circuit cases: Functional Claim “Raises the Bar for Enablement” In Amgen v. Sanofi and Regeneron (Fed. Cir. 2021) (available - Amgen case) the CAFC provided another anti-functional-limitation decision — this time rendering Amgen’s monoclonal antibody claims invalid.  [...]

Go to Top